Press Release tiltled Infomerics Upgrade Fredun Pharmaceuticals Credit Rating to BBB+, Boosts Financial Profile.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Infomerics Valuation and Rating has upgraded Fredun Pharmaceuticals' long-term bank facilities of ₹156.17 crore from IVR BBB to IVR BBB+ with a Stable outlook, while reaffirming the short-term rating at IVR A2. The upgrade reflects improved operational performance, stronger financial profile, and disciplined capital management across FY24 and FY25. In FY25, the company reported total revenues of ₹456 crore, EBITDA of ₹55 crore, and profit after tax of ₹21 crore. The company manufactures pharmaceutical formulations across generics, cosmeceuticals, nutraceuticals, and animal healthcare, with exports to Africa, Southeast Asia, CIS countries, and Latin America.
The upgrade signals stronger creditworthiness and may help the company secure better borrowing terms and greater financial flexibility for expansion. For shareholders, it is a positive indicator of improving fundamentals and reduced credit risk.